RBC Capital lowered the firm’s price target on Medtronic (MDT) to $101 from $105 but keeps an Outperform rating on the shares. The company’s initial FY26 EPS view was below estimates, with 4% y/y growth ex-tariffs due to higher rates of investments intended to position Medtronic for future growth, as well as due to the impacts from some below-the-line items, the analyst tells investors in a research note. RBC adds however that there is potential upside to Medtronic’s mid-single-digit organic revenue growth outlook.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target lowered to $98 from $100 at Mizuho
- Medtronic price target lowered to $92 from $94 at Baird
- Medtronic Reports Strong FY25 Results and Dividend Increase
- Medtronic’s Strong Financial Performance and Promising Growth Outlook Justify Buy Rating
- Medtronic’s Mixed Outlook: Hold Rating Amid Profitability Concerns and Strategic Initiatives
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue